tetano
Editor, Senior Moderator
Sci Rep
. 2025 Dec 29;15(1):44894.
doi: 10.1038/s41598-025-29183-z. Precision dosing of recombinant vaccinia vaccine via pillar-guided microneedle patch confers SARS-CoV-2 immunity
Kotaro Shobayashi[SUP] 1 [/SUP], Jongho Park[SUP] 2 [/SUP], Hoshimi Aoyagi[SUP] 2 [/SUP], Fumihiko Yasui[SUP] 3 [/SUP], Michinori Kohara[SUP] 3 [/SUP], Beomjoon Kim[SUP] 4 [/SUP]
Affiliations
Recent advances in microneedle array patch (MAP) technology have highlighted its potential for efficient and accessible vaccine delivery. In this study, we developed a pillar-guided MAP (PG-MAP) loaded with a recombinant vaccinia virus (r-DIs-S) expressing the SARS-CoV-2 spike (S) gene. Our fabrication method enabled precise localization of a high viral titer (> 9.4 ± 1.8 × 10⁶ PFU per patch), as verified by plaque assay. In vivo immunization in mice demonstrated that the r-DIs-S-loaded PG-MAP elicited robust S-protein-specific IgG and neutralizing antibody responses. Upon SARS-CoV-2 challenge, all PG-MAP-immunized mice survived and maintained their body weight, whereas the control groups experienced severe results. These results demonstrated that the PG-MAP platform enables precise dosing, maintains viral stability, and induces potent protective immunity, offering a promising alternative for decentralized, minimally invasive vaccination strategies against emerging infectious diseases.
Keywords: COVID-19 vaccination; Microneedle array patch; Minimally invasive administration; R-DIs-S; Vaccinia virus vector.
. 2025 Dec 29;15(1):44894.
doi: 10.1038/s41598-025-29183-z. Precision dosing of recombinant vaccinia vaccine via pillar-guided microneedle patch confers SARS-CoV-2 immunity
Kotaro Shobayashi[SUP] 1 [/SUP], Jongho Park[SUP] 2 [/SUP], Hoshimi Aoyagi[SUP] 2 [/SUP], Fumihiko Yasui[SUP] 3 [/SUP], Michinori Kohara[SUP] 3 [/SUP], Beomjoon Kim[SUP] 4 [/SUP]
Affiliations
- PMID: 41461806
- DOI: 10.1038/s41598-025-29183-z
Recent advances in microneedle array patch (MAP) technology have highlighted its potential for efficient and accessible vaccine delivery. In this study, we developed a pillar-guided MAP (PG-MAP) loaded with a recombinant vaccinia virus (r-DIs-S) expressing the SARS-CoV-2 spike (S) gene. Our fabrication method enabled precise localization of a high viral titer (> 9.4 ± 1.8 × 10⁶ PFU per patch), as verified by plaque assay. In vivo immunization in mice demonstrated that the r-DIs-S-loaded PG-MAP elicited robust S-protein-specific IgG and neutralizing antibody responses. Upon SARS-CoV-2 challenge, all PG-MAP-immunized mice survived and maintained their body weight, whereas the control groups experienced severe results. These results demonstrated that the PG-MAP platform enables precise dosing, maintains viral stability, and induces potent protective immunity, offering a promising alternative for decentralized, minimally invasive vaccination strategies against emerging infectious diseases.
Keywords: COVID-19 vaccination; Microneedle array patch; Minimally invasive administration; R-DIs-S; Vaccinia virus vector.